Zydus Lifesciences Limited (NSE: ZYDUSLIFE)

India flag India · Delayed Price · Currency is INR
964.80
-8.55 (-0.88%)
Dec 24, 2024, 3:30 PM IST
41.89%
Market Cap 970.81B
Revenue (ttm) 214.84B
Net Income (ttm) 43.03B
Shares Out 1.01B
EPS (ttm) 42.65
PE Ratio 22.76
Forward PE 21.36
Dividend 3.00 (0.31%)
Ex-Dividend Date Jul 26, 2024
Volume 841,321
Open 973.35
Previous Close 973.35
Day's Range 961.25 - 977.90
52-Week Range 666.75 - 1,324.30
Beta 0.42
Analysts n/a
Price Target n/a
Earnings Date Feb 4, 2025

About Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management... [Read more]

Sector Healthcare
Founded 1952
Employees 26,921
Stock Exchange National Stock Exchange of India
Ticker Symbol ZYDUSLIFE
Full Company Profile

Financial Performance

In 2023, Zydus Lifesciences's revenue was 195.47 billion, an increase of 13.40% compared to the previous year's 172.37 billion. Earnings were 38.60 billion, an increase of 96.88%.

Financial Statements

News

Zydus Lifesciences receives USFDA approval for Lidocaine and Prilocaine Cream USP

Zydus Lifesciences Limited has recently informed exchanges that the company received final approval from the United States Food and Drug Administration (USFDA) to manufacture Lidocaine and Prilocaine ...

5 days ago - Business Upturn

Pharma Sector Stocks: Torrent Pharma (+0.25%) rises; Glenmark (-2.29%), Aurobindo (-2.02%) decline

The pharma sector showed mixed trends during the session as of 12:15 AM. Torrent Pharma was the only gainer, rising ₹8.45 to ₹3,336.30 (+0.25%). Sun Pharma dipped ₹4.95 to ₹1,800.50 (-0.27%), and Dr. ...

11 days ago - Business Upturn

Zydus Lifesciences faces setback as SC denies interim relief in breast cancer drug case, sends matter back to Delhi HC

Shares of Zydus Lifesciences were under focus after the Supreme Court refused to grant interim relief to the company in a high-profile breast cancer drug patent case. The SC sent the case back to the ...

5 weeks ago - Business Upturn

Zydus Lifesciences’s market cap gains Rs 1,363 crore as stock surges 1.43%

Shares of Zydus Lifesciences Limited saw a modest rise, closing at ₹963.30, a 1.43% increase from the previous close of ₹949.75. This increase led to a gain of around ₹1,363.45 crore in the company’s ...

5 weeks ago - Business Upturn

Zydus Lifesciences Ltd (BOM:532321) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ...

Zydus Lifesciences Ltd (BOM:532321) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Regulatory Challenges

5 weeks ago - GuruFocus

Zydus Lifesciences stock drops 2% on Q2 results

Shares of Zydus Lifesciences fell more than 2% following the release of its Q2 financial results. The company’s total revenue saw a sharp decline of 41.39% quarter-on-quarter (QoQ) to ₹492.9 crore, th...

6 weeks ago - Business Upturn

Zydus Lifesciences Q2 FY25: Revenue up 20% YoY to Rs 5237 crore, Net Profit up 13.7% YoY

Zydus Lifesciences posted a strong performance for the quarter ending September 30, 2024 (Q2 FY25), with robust growth across key financial metrics on a year-over-year (YoY) basis. Net Profit: The com...

6 weeks ago - Business Upturn

Q2 results today: Hyundai Motor India, Bosch, Zydus Lifesciences, Nykaa, Unno Minda, 3M India, Natco Pharma, TBO Tek among companies to announce earnings

A diverse group of companies, including Hyundai Motor India, Bosch, Zydus Lifesciences, and FSN E-Commerce Ventures (Nykaa), are set to announce their Q2 FY24-25 financial results today. Here’s a list...

6 weeks ago - Business Upturn

Zydus Lifesciences receives WHO approval for ZyVac® TCV, making it eligible for UN procurement

Zydus Lifesciences Limited has received in-principle acceptability from the World Health Organization (WHO) for its indigenously developed typhoid conjugate vaccine, ZyVac® TCV, making it eligible for...

2 months ago - Business Upturn

Zydus Lifesciences gets USFDA approval for Fludrocortisone Acetate tablets

Zydus Lifesciences Limited has recently announced exchanges that the company received final approval from the United States Food and Drug Administration (USFDA) for the manufacture of Fludrocortisone ...

2 months ago - Business Upturn

Zydus Lifesciences shares decline nearly 3% after Exelixis wins patent ruling over MSN Labs’ Cabometyx copies – Know More

Zydus Lifesciences shares fell nearly 3% in Wednesday’s early trade after a U.S. federal judge ruled in favor of Exelixis Inc. in a patent dispute over Cabometyx, a blockbuster cancer drug. MSN Labora...

2 months ago - Business Upturn

Zydus and ICMR initiate Phase 2 trial of Desidustat for Sickle Cell Disease

Zydus Lifesciences Limited and the Indian Council of Medical Research (ICMR) have commenced a Phase 2 proof-of-concept clinical trial for Desidustat in patients with Sickle Cell Disease (SCD). This tr...

2 months ago - Business Upturn

Zydus Lifesciences receives USFDA approval for Paliperidone Extended-Release tablets

Zydus Lifesciences Limited has recently informed exchanges that the company received final United States Food and Drug Administration (USFDA) approval to manufacture Paliperidone Extended-Release Tabl...

2 months ago - Business Upturn

Stocks to Watch on Oct 3: Reliance Power, Ashoka Buildcon, CESC, SMS Pharma, PVR INOX, Zydus Lifesciences, Reliance Infra, and HealthCare Global in focus

Key stocks to watch include Ashoka Buildcon, CESC, SMS Pharmaceuticals, PVR INOX, HealthCare Global Enterprises, Zydus Lifesciences, Reliance Power, Reliance Infra, Vikas Lifecare, Eraaya Lifespaces, ...

2 months ago - Business Upturn

Zydus Lifesciences gets tentative approval from USFDA for Enzalutamide Tablets, 40 mg and 80 mg

Zydus Lifesciences Limited has recently informed exchanges that the company has received tentative approval from the United States Food and Drug Administration (USFDA) to manufacture Enzalutamide Tabl...

2 months ago - Business Upturn

Zydus receives EIR from USFDA for transdermal manufacturing facility

Zydus Lifesciences Limited announced that it has received an Establishment Inspection Report (EIR) from the USFDA for its transdermal patch manufacturing facility located at Pharmez, Ahmedabad. The in...

3 months ago - Business Upturn

CDRI finds protein-drug combo to treat osteoporosis induced by chronic kidney disease

After five years of research, CDRI discovers a promising protein-drug combo targeting osteoporosis induced by chronic kidney disease, partnering with Zydus Lifesciences to improve patient care.

3 months ago - The Times of India

Zydus receives USFDA approval for Enzalutamide Capsules

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Enzalutamide Capsules, 40 mg. These capsules are used in the treatment of meta...

3 months ago - Business Upturn

Zydus Lifesciences secures licensing and supply agreement for MRI contrast agents in the US

Zydus Lifesciences announced today that its wholly owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Vivit Pharmaceuticals (Vivit).

3 months ago - Business Upturn

Stocks to Watch: Reliance, Zydus Lifesciences, ONGC in focus today (Sept 11, 2024)

In today’s market, several stocks are expected to draw attention due to notable developments across various sectors. Stocks in the Green: Reliance Industries: Reliance Retail has entered into a 50/50 ...

3 months ago - Business Upturn

Zydus Lifesciences completes its Phase II(a) clinical trial of Usnoflast

Zydus, a leading discovery-based, global pharmaceutical company, has informed exchanges that the company has completed its Phase II(a) clinical study of NLRP3 inhibitor ‘Usnoflast (ZYIL1)’ in patients...

3 months ago - Business Upturn

Zydus, Cipla, Lupin, Divi’s: Pharma stocks surge after US House of Representatives passes Biosecure Act

Pharma stocks saw a significant uptick in early trading after the US House of Representatives passed the Biosecure Act, which aims to bolster the pharmaceutical supply chain and encourage domestic dru...

3 months ago - Business Upturn

Zydus Lifesciences shareholders approve Rs. 3 per share dividend

At the 29th Annual General Meeting of Zydus Lifesciences Limited, held virtually on August 9, 2024, shareholders approved a dividend of Rs. 3 per share for the financial year 2023-24. This represents ...

3 months ago - Business Upturn

Zydus Lifesciences gets warning letter from USFDA for injectables manufacturing facility at Jarod

Zydus Lifesciences informed exchanges on Tuesday that it has received a warning notice from the USFDA regarding its injectables manufacturing facility at Jarod near Vadodara. The USFDA’s Warning Lette...

4 months ago - Business Upturn

Zydus’ injectables mfg plant gets USFDA warning letter

Zydus Lifesciences' injectables manufacturing plant in Jarod near Vadodara receives a warning letter from USFDA for violations of manufacturing regulations. No data integrity issues reported.

4 months ago - The Times of India